MYB and lung carcinoma: Moreover, our findings may lead to new biomarkers as well as therapies that might target distinct LUAD subgroups associated with poor survival; small molecule inhibitors for MYB family members [60] as well as FOXM1 have been developed but have not yet been tested in lung cancer [61,62].